Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003 Sep 01; 102(5):1578-82.
-
Paul Gerard Guy Richardson, M.B.,B.S.
-
Daniel J. DeAngelo, Ph.D., M.D.
-
Richard M. Stone, M.D.
-
Vincent T. Ho, M.D.
-
Robert Jon Soiffer, M.D.
-
Martha Wadleigh, M.D.
-
Corey Stephen Cutler, M.D.
-
Joseph Harry Antin, M.D.